Evolus (NASDAQ:EOLS) Now Covered by Analysts at BTIG Research

Stock analysts at BTIG Research started coverage on shares of Evolus (NASDAQ:EOLS - Get Free Report) in a research note issued on Thursday, MarketBeat.com reports. The brokerage set a "buy" rating and a $21.00 price target on the stock. BTIG Research's price target would indicate a potential upside of 101.34% from the stock's previous close.

A number of other brokerages also recently issued reports on EOLS. HC Wainwright restated a "buy" rating and set a $27.00 price objective on shares of Evolus in a research report on Thursday, April 10th. Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Evolus in a report on Wednesday, April 9th. Finally, Barclays lifted their price objective on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $23.75.

Evolus Price Performance

EOLS stock traded up $0.05 during trading on Thursday, hitting $10.43. 193,900 shares of the company's stock traded hands, compared to its average volume of 659,511. Evolus has a 52 week low of $8.67 and a 52 week high of $17.82. The stock has a market capitalization of $663.21 million, a price-to-earnings ratio of -11.44 and a beta of 0.97. The business has a fifty day simple moving average of $12.54 and a 200 day simple moving average of $13.05. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47.

Insider Activity at Evolus

In other news, insider Rui Avelar sold 27,904 shares of the business's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $370,007.04. Following the completion of the sale, the insider now owns 362,467 shares in the company, valued at approximately $4,806,312.42. The trade was a 7.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of Evolus stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $60,147.36. Following the transaction, the chief marketing officer now directly owns 95,671 shares in the company, valued at approximately $1,268,597.46. The trade was a 4.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 60,575 shares of company stock worth $794,369 in the last 90 days. 6.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC grew its stake in Evolus by 268.0% in the third quarter. Barclays PLC now owns 93,662 shares of the company's stock valued at $1,518,000 after purchasing an additional 68,213 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Evolus by 9.8% during the 4th quarter. Principal Financial Group Inc. now owns 33,370 shares of the company's stock worth $368,000 after acquiring an additional 2,989 shares in the last quarter. Jane Street Group LLC lifted its position in Evolus by 47.0% during the third quarter. Jane Street Group LLC now owns 91,899 shares of the company's stock valued at $1,489,000 after acquiring an additional 29,396 shares during the last quarter. Lord Abbett & CO. LLC grew its holdings in Evolus by 23.4% in the third quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company's stock worth $16,126,000 after purchasing an additional 188,685 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Evolus by 63.5% during the third quarter. JPMorgan Chase & Co. now owns 169,926 shares of the company's stock worth $2,753,000 after purchasing an additional 65,972 shares in the last quarter. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.